The proceeds from the sale will go toward the planned acquisition of Curetis and to support the ongoing submission of its technology to US regulators.
Exagen, which develops and markets autoimmune tests, went public on the Nasdaq today and expects gross proceeds of $50.4 million from its IPO.
The company announced its European subsidiary priced an offering of €6.20 billion ($6.83 billion) in senior notes to fund part of its purchase of GE's Biopharma business.
The firm replaced an existing $4 billion credit facility with a $5 billion one, and entered into a new $5 billion revolving credit facility.
The disclosure comes less than a week after the company said that it was out of compliance with the Nasdaq's minimum shareholder equity requirement.
The firm it plans to offer from time to time units of its common stock, preferred stock, one or more debt securities, warrants, or rights to such securities in one or more series.
The company plans to sell 9 million shares at $19.00 per share, which is expected to bring in $171.0 million in gross proceeds.
Invitae hasn't priced the offering yet or disclosed how many shares it will offer, but it expects net proceeds to range from $117.1 million to $134.7 million.
In an SEC document, the company said net proceeds are expected to be $5.8 million and will be used to support an anticipated submission to the FDA, among other things.
The company's revenues in the quarter rose to $221.9 million from $161.0 million in Q4 2017, but it missed the consensus Wall Street estimate of $245.3 million.